Thermon Group Holdings News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.09.24	Thermon Group Appoints Jan L. Schott As New CFO (RTTNews)
10.11.17	Avis aux médias - Son Excellence participera aux évènements organisés à l'occasion du jour du Souvenir à Ottawa (PR Newswire)
04.10.17	Thermon To Buy CCI Thermal Technologies For C$258 Mln In Cash - Quick Facts (RTTNews)
10.07.17	ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement (PR Newswire)
10.07.17	ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement (PR Newswire)
08.06.17	ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress, Barcelona, Spain (PR Newswire)
08.06.17	ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress, Barcelona, Spain (PR Newswire)
24.05.17	ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary (PR Newswire)
24.05.17	ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary (PR Newswire)
11.05.17	ThromboGenics Business Update - Q1 2017 (PR Newswire)
11.05.17	ThromboGenics Business Update - Q1 2017 (PR Newswire)
02.05.17	New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore (PR Newswire)
02.05.17	New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore (PR Newswire)
20.04.17	ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema (PR Newswire)
20.04.17	ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema (PR Newswire)
16.03.17	ThromboGenics Business Update - FY 2016 (PR Newswire)
16.03.17	ThromboGenics Business Update - FY 2016 (PR Newswire)
10.01.17	ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME) (PR Newswire)
10.01.17	ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME) (PR Newswire)
07.04.15	Thermon Reveals Acquisition Of Sumac (RTTNews)
23.12.14	Thermon Agrees To Buy Unitemp (RTTNews)
29.05.14	Thermon Profit Rises On Lower Expenses, Yet Misses Street (RTTNews)
23.10.13	National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics' JETREA® for Treatment of a Broad Range of Patients with Vitreomacular Traction (VMT),... (PR Newswire)
23.10.13	National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics' JETREA® for Treatment of a Broad Range of Patients with Vitreomacular Traction (VMT),... (PR Newswire)
21.10.13	ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA (PR Newswire)
21.10.13	ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA (PR Newswire)
17.10.13	Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole (PR Newswire)
17.10.13	Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole (PR Newswire)
01.10.13	Euretina Presentation "Adoption of JETREA® in My Everyday Practice" Confirms Need for a New Paradigm in Treatment of Symptomatic VMA/ VMT, Including Those Cases Associated with MH (PR Newswire)
01.10.13	Euretina Presentation "Adoption of JETREA® in My Everyday Practice" Confirms Need for a New Paradigm in Treatment of Symptomatic VMA/ VMT, Including Those Cases Associated with MH (PR Newswire)
30.09.13	ThromboGenics Establishes Level 1 ADR Program for US Investors (PR Newswire)
30.09.13	ThromboGenics Establishes Level 1 ADR Program for US Investors (PR Newswire)
05.09.13	ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema (PR Newswire)
05.09.13	ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema (PR Newswire)
02.09.13	UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA® for Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
02.09.13	UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA® for Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
29.08.13	ThromboGenics Business Update H1 2013 (PR Newswire)
29.08.13	ThromboGenics Business Update H1 2013 (PR Newswire)
16.08.13	Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion (PR Newswire)
16.08.13	Health Canada Approves ThromboGenics' JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion (PR Newswire)
02.08.13	Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)
02.08.13	Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Thermon Group Holdings Inc.

Aktien Top/Flop

Meistgelesene Nachrichten